Cortexyme, a company focused on degenerative disorders, appointed Leslie Holsinger, PhD as Vice President of Preclinical Development.
Most recently Dr. Holsinger served as Vice President of Biology at Virobay, developing cathepsin inhibitor therapeutics and clinical biomarkers for neuropathic pain, autoimmune disease, fibrosis, and Alzheimer’s.
“Leslie brings a wealth of experience in protease inhibition and drug development to Cortexyme,” said Casey Lynch, CEO of Cortexyme. “We look forward to benefitting from Leslie’s perspective and experience as we continue to develop our lead compounds for Alzheimer’s and other disorders.”
“By targeting bacterial proteases, Cortexyme is taking a very novel and promising approach,” said Dr. Holsinger.
“I look forward to working with the team at Cortexyme
to turn these exciting discoveries into therapeutics
for patients in need.”
Prior to Virobay, Dr. Holsinger served as Associate Director of Cell Biology at Celera, where she was responsible for translational and discovery biology. Dr. Holsinger also served as Group Leader in discovery research at Sugen, Inc., a Pfizer company, where she assisted in drug discovery programs focused on kinase and phosphatase inhibitor drug development in multiple therapeutic areas. Dr. Holsinger received a B.A. in biochemistry from Occidental College and a Ph.D. in molecular and cellular biology from Northwestern University. She also completed post-doctoral studies at Stanford University.
Cortexyme is a private company based in San Francisco California developing therapeutics to alter the course of Alzheimer’s and other disorders of aging. Cortexyme is targeting a specific, undisclosed pathogen tied to degeneration. The target has been validated in a number of animal models and Cortexyme is currently testing patent-pending lead therapeutics in preclinical studies. For more information on Cortexyme, visit www.cortexyme.com.